



MICREOS

FOR IMMEDIATE RELEASE



**Micreos' Alternative to antibiotics, based on endolysin technology, was chosen at the EU conference in Tallinn as one of Europe's most important innovations. The Dutch company was also the public's favorite. Finalists from ten other countries from across Europe will pitch at the Ridderzaal (Hall of Knights) in The Hague on April 24, 2018.**

The Hague, December 7, 2017 - Micreos' alternative to antibiotics made it through the semi-finals of Ideas from Europe (the Eurovision Song Contest for innovation) in Estonia on November 22, 2017. In the presence of EU Commissioner Mrs. E. Bieńkowska and the Minister for Economic Affairs for Estonia Mrs. K. Simson, Micreos was unanimously chosen as one of the 10 finalists from among 28 participating European countries. Joining Micreos will be ten others at the Ridderzaal (Hall of Knights), to present their ideas and be proclaimed Europe's best innovation. Micreos' technology, already available in its Gladskin products, has had a life changing impact for many people suffering from inflammatory skin conditions such as eczema, acne and rosacea.

**Watch: the three minute semi-final pitch from CEO Mark Offerhaus**

<https://www.youtube.com/watch?v=e1f6Al-kC7I>

**Watch: the eight minute clip from the BBC explaining the unique technology and possible applications.**

<http://www.bbc.co.uk/programmes/p04s9x5x>

Having won the national heats in September, where guest of honour, Kofi Annan, winner of the Nobel Peace Prize, reflected: "I am really excited about Micreos' alternative to antibiotics", Micreos presented its endolysin technology for combatting unwanted bacteria in front of a pan-European panel of policy makers, experts, entrepreneurs, and investors. As the representative of the Netherlands, CEO Mark Offerhaus had three minutes to introduce the winning pitch in front of a live audience.

Micreos CEO Mark Offerhaus: "Antibiotic-resistance is an enormous global problem. With our technology it is possible for the first time to kill only the unwanted bacteria while preserving the microbiome, comprising billions of bacteria essential for our health. We've already been able to help many people suffering from inflammatory skin diseases and wound infections caused or aggravated by the *Staphylococcus aureus* bacteria, including the resistant MRSA. But this marks only the beginning. There's no need to wait and no time to lose."

#### **About Ideas from Europe**

Ideas from Europe is a European platform aimed at promoting the development of ideas for society's major challenges. The platform met in November in Tallinn, during Estonia's tenure as EU chair. The concept behind Ideas from Europe is that the involvement of the public at large can propel relevant breakthrough innovations.

See: <https://ideasfrom.eu>

#### **About Micreos**

Micreos develops endolysin- and phage technology that enables targeted killing of only unwanted bacteria. The company is considered the leader in this exciting new field. Micreos runs its own production and R&D centre for endolysins in Bilthoven and for phages in Wageningen 'Food Valley'. Micreos' head office is in The Hague. The company works together with ETH Zurich and numerous medical and technology centres, including Erasmus MC (Rotterdam), Public Health Lab Kennemerland, the Dutch Burn Centres (Beverwijk) and many others. Gladskin is a Micreos Human Health brand ([www.gladskin.com](http://www.gladskin.com)). Micreos Food Safety produces the FDA approved products PhageGuard LISTEX, against *Listeria*, and Phageguard S, against *Salmonella* ([www.phageguard.com](http://www.phageguard.com)).

For further information: Dirk de Meester: +31 6 46048503 - [d.demeester@micreos.com](mailto:d.demeester@micreos.com)

Websites: [www.micreos.com](http://www.micreos.com) [www.gladskin.com](http://www.gladskin.com) [www.phageguard.com](http://www.phageguard.com)